Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: A synopsis

American Journal of Managed Care

Volumn 20, Issue 7 SUPPL., 2014, Pages

  Gibofsky, Allan ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPITOPE; GAMMA INTERFERON; HEAT SHOCK PROTEIN; HLA DRB1 ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 26; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; RHEUMATOID FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ANTIRHEUMATIC AGENT;

ADAPTIVE IMMUNITY; ALLELE; ANGIOGENESIS; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BONE EROSION; BREAST FEEDING; BYSTANDER EFFECT; CAPILLARY FLOW; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MIGRATION; CEREBROVASCULAR ACCIDENT; CHROMOSOME 6; CLINICAL DISEASE ACTIVITY INDEX; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DAS28; DENDRITIC CELL; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS INFECTION; ERYTHROCYTE SEDIMENTATION RATE; ESCHERICHIA COLI INFECTION; FUNCTIONAL STATUS; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HEALTH ASSESSMENT QUESTIONNAIRE; HERITABILITY; HUMAN; HYPOXIA; IMMUNE RESPONSE; INNATE IMMUNITY; INTRACELLULAR SIGNALING; ISCHEMIC HEART DISEASE; JOINT BIOPSY; LEUKOCYTE; LYMPHOCYTE; MACROPHAGE; MANAGED CARE; MEDICAL HISTORY; MOLECULAR MIMICRY; MONOCYTE; NEUTROPHIL; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL CONTRACEPTIVE USE; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN MOTIF; PROTEUS INFECTION; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; ROUTINE ASSESSMENT OF PATIENT INDEX DATA; SIMPLIFIED DISEASE ACTIVITY INDEX; SMOKING; SYNOVIOCYTE; SYNOVITIS; SYNOVIUM; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; UPREGULATION; ARTHRITIS, RHEUMATOID; CLASSIFICATION; DISEASE COURSE; EUROPE; HEALTH INSURANCE; MEDICAL SOCIETY; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; UNITED STATES;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; EUROPE; HUMANS; MANAGED CARE PROGRAMS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84905647565     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356-361. (Pubitemid 40852711)
2. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62-68.
3. Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis. 2005;64(11):1595-1601. (Pubitemid 41532043)
4. Dominick KL, Ahern FM, Gold CH, Heller DA. Health-related quality of life among older adults with arthritis. Health Qual Life Outcomes. 2004;2:5.
5. Hulsemann JL, Mittendorf T, Merkesdal S, et al. Direct costs related to rheumatoid arthritis: the patient perspective. Ann Rheum Dis. 2005;64(10):1456-1461. (Pubitemid 41623857)
6. Sokka T, Kautiainen H, Pincus T, et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther. 2010; 12(2):R42.
7. Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study [published online February 18, 2014]. Ann Rheum Dis.
8. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-324. (Pubitemid 18091653)
9. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Eng J Med. 2011;365(23):2205-2219.
10. MacGregor AJ, Snieder H, Rigby AS, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 2000;43(1):30-37. (Pubitemid 30368210)
11. Berglin E, Johansson T, Sundin U, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis. 2005;65(4): 453-458.
12. Karlson EW, Chang SC, Cui J, et al. Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):54-60.
13. Thomson W, Barton A, Ke X, et al. Rheumatoid arthritis association at 6q23. Nat Genet. 2007;39(12):1431-1433. (Pubitemid 350191348)
14. Pikwer M, Bergstrom U, Nilsson JA, Jacobsson L, Berglund G, Turesson C. Breast feeding, but not use of oral contraceptives, is associated with a risk of rheumatoid arthritis. Ann Rheum Dis. 2009;68(4):526-530.
15. Munz C, Lunemann JD, Getts M, Miller SD. Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol. 2009;9(4):246-258.
16. Balsa A, Cabezon A, Orozco G, et al. Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor. Arthritis Res Ther. 2010;12(2):R62.
17. van de Sande MG, de Hair MJ, van der Leij C, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis. 2011;70(5):772-777.
18. Nielen MM, van Schaardenburg D, Reesink H, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380-386. (Pubitemid 38198821)
19. Lund-Olesen K. Oxygen tension in synovial fluids. Arthritis Rheum. 1970;13(6):769-776.
20. Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res. 2002;4(suppl 3):S81-S90.
21. Akhavani MA, Madden L, Buysschaert I, Sivakumar B, Kang N, Paleolog EM. Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):R64.
22. Lebre M, Jongbloed, S, Tas S, Smeets TJ, McInnes IB, Tak PP. Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP- dendritic cells with distinct cytokine profiles. Am J Pathol. 2008;172(4):940-950. (Pubitemid 351519991)
23. Podojil JR, Miller SD. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol Rev. 2009;229(1):337-355.
24. Pieper J, Herrath J, Raghavan S, Muhammad K, Vollenhoven Rv, Malmstrom V. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol. 2013;14:34.
25. Lohr J, Knoechel B, Caretto D, Abbas AK. Balance of Th1 and Th17 effector and peripheral regulatory T cells. Microbes Infect. 2009;11(5):589-593.
26. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950-957. (Pubitemid 47300009)
27. Corvaisier M, Delneste Y, Jeanvoine H, et al. IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation. PLoS Biol. 2012; 10(9):e1001395.
28. Beech JT, Andreakos E, Ciesielski C, Green P, Foxwell BM, Brennan FM. T-cell contact-dependent regulation of CC and CXC chemokine production in monocytes through differential involvement of NFkB: implications for rheumatoid arthritis. Arthritis Res Ther. 2006;8(6):R168.
29. Tran CN, Lundy SK, White PT, et al. Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells. Am J Pathol. 2007;171(5):1588-1598. (Pubitemid 350158319)
30. Finnegan A, Ashaye S, Hamel KM. B effector cells in rheumatoid arthritis and experimental arthritis. Autoimmunity. 2012;45(5):353-363.
31. Cohen SB, Emery P, Greenwald MW, et al REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-2806. (Pubitemid 44497758)
32. Rituxan [prescribing information]. South San Francisco, CA: Genentech, Inc; 2013.
33. Huang QQ, Pope RM. The role of toll-like receptors in rheumatoid arthritis. Curr Rheumatol Rep. 2009;11(5):357-364.
34. Mavers M, Ruderman EM, Perlman H. Intracellular signal pathways: potential for therapies. Curr Rheumatol Rep. 2009; 11(5):378-385.
35. Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253-261.
36. Bombara MP, Webb DL, Conrad P, et al. Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines. J Leukoc Biol. 1993;54(5):399-406. (Pubitemid 23347838)
37. Muller-Ladner U, Kriegsmann J, Franklin BN, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol. 1996;149(5):1607-1615. (Pubitemid 26363967)
38. Smolen JC, Aletaha D, Bijlsma J, et al; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-637.
39. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(5 suppl 39):S93-S99. (Pubitemid 46657516)
40. Castrejon I, Ortiz AM, Toledano E, et al. Estimated cutoff points for the 28-joint disease activity score based on C-reactive protein in a longitudinal register of early arthritis. J Rheumatol. 2010;37(7):1439-1443.
41. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003;42(2):244-257. (Pubitemid 36305610)
42. Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology. 2008;47(3):345-349. (Pubitemid 351267204)
43. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727-735.
44. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796-R806.
45. Maska L, Anderson J, Michaud K. Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL). Arthritis Care Res. 2011;63(suppl 11):S4-S13.
46. Tugwell P, Idzerda L, Wells GA. Generic quality-of-life assessments in rheumatoid arthritis. Am J Managed Care. 2007;13(suppl 9):S224-S236.
47. Felson DT, Smolen JS, Wells G, et al American College of Rheumatology; European League Against Rheumatism. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573-586.
48. Shahouri SH, Michaud K, Mikuls TR. Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum. 2011;63(11):3204-3215.
49. Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission. Arthritis Rheum. 2006;54(12):3761-3773.
50. van den Broek M, Dirven L, Kroon HM, et al. Early local swelling and tenderness are associated with large-joint damage after 8 years of treatment to target in patients with recent-onset rheumatoid arthritis. J Rheumatol. 2013;40(5):624-629.
51. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625-639.
52. McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis. 1998;57(6):350-356. (Pubitemid 28378310)
53. Cutolo M, Kitas GD, van Riel PL. Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. Seminars Arthritis Rheum. 2014;43(4):479-488.
54. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690-1697.
55. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581.